Abstract. The furanosylated indolocarbazole K252a belongs to a family of microbial alkaloids that also includes staurosporine, which is known to inhibit proliferation, stimulate apoptosis and induce the cell cycle arrest of cancer cells. To elucidate the involvement of K252a in endometrial cancer, we investigated the effects of K252a on three endometrial cancer cell lines. Endometrial cancer cells were treated with K252a and its effect on cell growth, cell cycle and related measurements was assessed. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays showed that the endometrial cancer cell lines were sensitive to the growth inhibitory effect of K252a, although normal endometrial epithelial cells were viable after treatment with the same doses of K252a that induced the growth inhibition of endometrial cancer cells. Cell cycle analysis indicated that their exposure to K252a decreased the proportion of cells in the S phase and increased the proportion of cells in the G0/G1 phase of the cell cycle. TUNEL assays demonstrated that K252a induced apoptosis. This occurred in concert with an altered expression of p21 WAF1 and bcl-2 proteins related to the G0/G1 phase of the cell cycle and apoptosis. These results raise the possibility that K252a may prove to be particularly effective in the treatment of endometrial cancers.
IntroductionK252a is a microbial alkaloid, an indolocarbazole derivative, isolated from the culture broth of the Nocardiopsis species. K252a was initially isolated as a potent inhibitor of the Ca 2+ messenger system and is a member of a family of related compounds (K252a, b, c and d) (1). These K252 compounds are structurally similar to staurosporine, which is known to inhibit glioma cell growth (2). The chemical structure of CBHA is shown in Fig. 1.K252a was found to inhibit protein kinase C (3,4), the cAMP-(3) and cGMP-dependent protein kinase (3), myosine light chain kinase (5), Ca 2+ /calmodulin-dependent protein kinases (CaMKs) (6) and cell cycle regulatory kinases such as Cdc2 (7). Specifically, K252a blocks the nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) activity in rat pheochromocytoma PC-12 and neuroblastoma cell lines by inhibiting TrkA and -B tyrosine kinase activity (8-10).As previously reported, K252a inhibited the proliferation of human hepatoma cells by inducing G0/G1 arrest (11) and blocked the platelet-derived growth factor (PDGF) receptor in glioma cells and inhibited proliferation (12). It was shown to potently inhibit c-Met autophosphorylation, HGF-mediated cell scattering and c-Met-driven proliferation in gastric carcinoma cells. Moreover, it was reported to cause a reversion of tumorigenicity in fibroblasts transformed with an oncogenic form of c-Met (13). However, the effect of K252a on endometrial cancer cells has yet to be adequately described.On the basis of these observations, we examined the effects of K252a on three endometrial cancer cell lines for the first time.
Materials and methodsCell lines. The Ishikawa human endometrial ca...